Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
نویسندگان
چکیده
منابع مشابه
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
Ferric citrate (FC) has demonstrated efficacy as a phosphate binder and reduces the requirements for erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron in dialysis patients. We developed a net budgetary impact model to evaluate FC vs. other phosphate binders from the vantage of a large dialysis provider. We used a Markov microsimulation model to simulate mutually referential lon...
متن کاملComment on: “Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode”
In 2012, total treatment costs for end-stage renal disease (ESRD) [in-center dialysis and outpatient costs combined] were estimated to be about US$88,000 per person per year [1]. For payers, this represents over US$7000 per member per month (PMPM) in expenses, a substantial burden. Therefore, analyses of ESRD costs are vital. Brunelli et al. conducted a budget impact analysis of a new phosphate...
متن کاملinvestigating the feasibility of a proposed model for geometric design of deployable arch structures
deployable scissor type structures are composed of the so-called scissor-like elements (sles), which are connected to each other at an intermediate point through a pivotal connection and allow them to be folded into a compact bundle for storage or transport. several sles are connected to each other in order to form units with regular polygonal plan views. the sides and radii of the polygons are...
Ferric citrate (auryxia) for the treatment of hyperphosphatemia.
Ferric citrate (Auryxia) for the treatment of hyperphosphatemia.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs in R&D
سال: 2017
ISSN: 1174-5886,1179-6901
DOI: 10.1007/s40268-016-0163-7